| As of Friday's close, MDCX had two different analyst targets pointing to a significant amount of upside potential.
Jason Kolbert of D. Boral Capital has given MDCX a $27 target representing a potential upside over 1,200% from last week's close.
Additionally, Jason McCarthy of Maxim Group has provided a $20 target suggesting 850+% potential upside from last week's close.
Could (Nasdaq: MDCX) be undervalued from current chart levels? -----
No. 4 MDCX Potential Catalyst - Medicus Seeks FDA Consent To Fast Track Clinical Development Program With Submission Of Type C Meeting Request.
Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)
The Company's aim is to seek FDA consent to fast track the Clinical Development Program to treat Basal Cell Carcinoma (BCC) of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays (D-MNA)
Philadelphia, Pennsylvania--(Newsfile Corp. - July 8, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive package to the United States Food and Drug Administration (the "FDA") seeking a Type C meeting with the FDA during the week of October 6th, 2025.
The purpose of the Type C meeting is to formally discuss the D-MNA product development and gain further alignment on the clinical pathway. The Company's aim is to gain the FDA's consent to fast-track the clinical development program and seek feedback on future clinical plans for the D-MNA development program. ...
...
Read the full article here. -----
No. 5 MDCX Potential Catalyst - A Definitive Agreement Moves Medicus Pharma A Step Closer To A Game-Changing Acquisition.
Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK
Antev Shareholders to Receive Aggregate ~17% Equity Stake in Medicus plus US$65Mn in Contingent Payments
Philadelphia, Pennsylvania--(Newsfile Corp. - June 30, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd. ("Antev"), a UK-based clinical-stage drug development company, announced today that they have entered into a definitive agreement dated June 29, 2025 (the "Definitive Agreement") pursuant to which Medicus has agreed to acquire all of the issued and outstanding shares of Antev (the "Antev Shares") on a share exchange basis (the "Transaction").
...
Read the full article here. -----
(Nasdaq: MDCX) Recap - These 5 Potential Breakout Catalysts Lead The Way
No. 1 - A Low Float Could Create The Environment For Heightened Volatility.
No. 2 - Medicus Signs MOU With Helix Nanotechnologies Inc. To Combine Key Company Platforms.
No. 3 - A Pair Of Analyst Targets Suggest Major Upside Potential (Triple-Digit!).
No. 4 - Medicus Seeks FDA Consent To Fast Track Clinical Development Program With Submission Of Type C Meeting Request.
No. 5 - A Definitive Agreement Moves Medicus Pharma A Step Closer To A Game-Changing Acquisition. -----
Consider Medicus Pharma Ltd. (Nasdaq: MDCX) for your radar and be on watch for updates soon.
Sincerely, Jaks Swift Fierce Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 08/14/2025 and ending on 08/20/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty five thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (MDCX:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/mdcx-tz9r4/#details | 
No comments:
Post a Comment